These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25836938)

  • 1. First-line treatment of metastatic disease: cisplatin-ineligible patients.
    Cathomas R; De Santis M; Galsky MD
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):329-40, x. PubMed ID: 25836938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Godbold J; Oh WK; Bamias A
    Cancer; 2013 Aug; 119(16):3012-9. PubMed ID: 23720216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.
    Abida W; Bajorin DF; Rosenberg JE
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):319-28, ix-x. PubMed ID: 25836937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current chemotherapeutic options for the treatment of advanced bladder cancer: a review.
    Pliarchopoulou K; Laschos K; Pectasides D
    Urol Oncol; 2013 Apr; 31(3):294-302. PubMed ID: 20843708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for urothelial carcinoma.
    Gartrell BA; Sonpavde G
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
    Galsky MD; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
    Urol Oncol; 2014 Jan; 32(1):30.e15-21. PubMed ID: 23428534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
    Koufopoulou M; Miranda PAP; Kazmierska P; Deshpande S; Gaitonde P
    Cancer Treat Rev; 2020 Sep; 89():102072. PubMed ID: 32769039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum analogue combination chemotherapy: cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors.
    Sengeløv L; Nielsen OS; Kamby C; von der Maase H
    Cancer; 1995 Nov; 76(10):1797-803. PubMed ID: 8625050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.
    Vaughn DJ
    Cancer Treat Rev; 2008 Jun; 34(4):328-38. PubMed ID: 18262363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
    Sternberg CN; Bellmunt J; Sonpavde G; Siefker-Radtke AO; Stadler WM; Bajorin DF; Dreicer R; George DJ; Milowsky MI; Theodorescu D; Vaughn DJ; Galsky MD; Soloway MS; Quinn DI;
    Eur Urol; 2013 Jan; 63(1):58-66. PubMed ID: 22917984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
    Pectasides D; Pectasides M; Economopoulos T
    Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01).
    Culine S; Fléchon A; Guillot A; Le Moulec S; Pouessel D; Rolland F; Ravaud A; Houédé N; Mignot L; Joly F; Oudard S; Gourgou S
    Eur Urol; 2011 Dec; 60(6):1251-7. PubMed ID: 21924547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy for bladder cancer.
    Sonpavde G; Lerner SP
    Oncology (Williston Park); 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694. PubMed ID: 18247016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?
    Mertens LS; Meijer RP; Kerst JM; Bergman AM; van Tinteren H; van Rhijn BW; Horenblas S
    J Urol; 2012 Oct; 188(4):1108-13. PubMed ID: 22901581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
    Wei XX; Werner L; Teo MY; Rosenberg JE; Koshkin VS; Grivas P; Szabados B; Morrison L; Powles T; Carril-Ajuria L; Castellano D; Velho PI; Hahn NM; McKay RR; Raggi D; Necchi A; Kanesvaran R; Alerasool P; Gaines J; Galsky M; Bellmunt J; Sonpavde G
    J Urol; 2021 Feb; 205(2):414-419. PubMed ID: 32935617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
    Rossi L; Santoni M; Crabb SJ; Scarpi E; Burattini L; Chau C; Bianchi E; Savini A; Burgio SL; Conti A; Conteduca V; Cascinu S; De Giorgi U
    Ann Surg Oncol; 2015 Apr; 22(4):1377-84. PubMed ID: 25234022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
    Galsky MD; Krege S; Lin CC; Hahn N; Ecke T; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
    Cancer; 2013 Aug; 119(16):3020-6. PubMed ID: 23720197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer.
    Wosnitzer MS; Hruby GW; Murphy AM; Barlow LJ; Cordon-Cardo C; Mansukhani M; Petrylak DP; Benson MC; McKiernan JM
    Cancer; 2012 Jan; 118(2):358-64. PubMed ID: 21717438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review and outlook for the role of paclitaxel in urothelial carcinoma.
    Vaughn DJ
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):117-22. PubMed ID: 10190793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
    Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Pond G; Godbold J; Oh WK; Bamias A
    Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.